Loading peptide directory…
Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | LY3437943, Triple agonist GLP-1/GIP/GCG, GGG triple agonist, Lilly triple G |
| Category | Metabolic |
| Formula | — |
| Molecular weight | 4731 Da |
| Half-life | ~6 days |
| Mechanism (summary) | Retatrutide (LY3437943) is a once-weekly synthetic peptide and the most-advanced "triple G" agonist in development. A single molecule activates all three of GLP-1R, GIPR, and GCGR. As of 2026 it remains investigational, with peer-reviewed phase 2 obesity data and company-reported phase 3 readouts in type 2 diabetes; no marketed label exists yet. |
| Dosing notes | Investigational, subcutaneous, once weekly. Trial regimens span 1, 4, 8, and 12 mg, with dose-escalation schedules such as 1 → 4 → 12 mg or 2 → 4 → 8 → 12 mg. There is no approved label and no formal contraindication list yet. |
| Storage |
Unspecified in publicly available official sources. Retatrutide has no public prescribing information; no authoritative patient-facing storage instruction should be inferred from precedent. |
| Read more | Full reference → |
|---|